Wuyou Tiaodong Medical Secures Nearly RMB 100 Million in Series A Funding to Advance PFO Diagnosis and Treatment Solutions

Smart Medical Device Network NewsRecently, WYTD MEDICAL TECHNOLOGY (SHENZHEN) CO., LTD. (referred to as"WYTD" announced the completion of nearly 100 million yuanARound of financing, led by Taiping Healthcare Fund, with Yangtze River Capital following.

After the completion of this round of financing, the shareholder lineup of WYTD has been further enriched, forming a diversified capital structure that includes insurance funds, securities firms, industry listed companies, and venture capital institutions. This provides a solid financial and resource foundation for the company's next stage of industrialization and commercialization.

It is reported that the proceeds of this round of financing will be mainly used to accelerate its patent foramen ovale (PFO, Patent Foramen Ovale) The industrialization and commercialization process of a complete solution, further improving the innovative product layout in the field of structural heart disease.

Data shows that WYTD MEDICAL TECHNOLOGY (SHENZHEN) CO., LTD. is an innovative enterprise focusing on the treatment of heart disease, especially structural heart disease through implants and interventions. The company has passed the national highNewTechOperationThe company has been recognized as an internship base of Sichuan University, a high-growth enterprise in Pingshan District, and a technology-based small and medium-sized enterprise, among others.

The company's products mainly include five innovative products such as fully automatic cardiac shunt diagnostic equipment, hyper-compliant balloons, and degradable occlusion systems. The goal of the products is to provide a complete set of comprehensive solutions.PFODiagnosis and treatment plans, according to the current registration progress, the product will be launched from2023Will start to be launched successively at the end of the year.

As early as2023In the year, the company announced that it has completed an angel round of financing worth nearly ten million yuan. The investor in this round is Tsinghua-affiliated capital, Lihua Qingtong. The funds from this round of financing will be mainly used for product development, talent acquisition, and construction.2New Plant Decoration.

According to publicly available information,At the beginning of the company's establishment, a large amount of research was conducted, revealing that patent foramen ovale (PFO) is not only very difficult to diagnose, but also after interventional closure, there are still...15-30%Some patients have residual shunts. There are also complications after the implantation of metal occluders, which may affect other surgeries that require trans-septal puncture, such as left atrial appendage occlusion, mitral valve clipping, and other cardiac interventional procedures. Additionally, some patients may experience complications such as nickel-titanium allergies or tissue abrasion caused by metal occluders.

Editor's Express

1

Enterprise interviews, in-depth coverage and promotion of products and technologies, industry report consulting, contributions;

2

Contact: 13714842321 (Same on WeChat)